Some countries release Novartis flu vaccines; Pharmalink, Patheon hook up on new drug;

> Canada and Switzerland have lifted their bans on Novartis ($NVS) flu vaccines saying they are satisifed with information they have received from the company. Story

> Sweden-based Pharmalink has signed a manufacturing contract with Patheon for Nefecon that is in development to address the pathology of IgA nephropathy. Story

> Officials in Tanzania have accused a manufacturer there of having produced counterfeit HIV medication. Story 

> Discovery Park, the site of a former Pfizer ($PFE) plant in the U.K., has been given Enterprise Zone status so it can provide cost incentives to help it attract the life science clients it is seeking. Story 

> Rite Aid ($RAD) reported a 1.1% drop in same-store sales in October as generic drug further captured more market share from branded products. Item

> Generics giant Teva Pharmaceutical Industries ($TEVA) displayed the flip side of the patent cliff phenomenon by reporting better than expected earnings today. Story 

And Finally... The FDA has announced a voluntary recall of Chinese bee pollen that contains undeclared Sibutramine, a previously approved controlled substance that was removed from the U.S. market in October 2010 for safety reasons. Release


Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.